MarijoBilusic, William LDahut. (2011) Cabazitaxel: a new drug for metastatic prostate cancer. Asian Journal of Andrology 13 , 185-186 /Marijo, BilusicWilliam L, Dahut. (2011) Cabazitaxel: a new drug for metastatic prostate cancer. Asian Journal of Andrology 13 , 185-186 /...
Prostate cancer cells. Credit: NIH Image Gallery Survival rates for men with metastatic prostate cancer have increased by an average of six months, something which coincides with the gradual introduction of "dual treatment" since 2016. This is according to a register study of all Swedish men diag...
More information:Vicenç Ruiz de Porras et al, Dual inhibition of MEK and PI3Kβ/δ–a potential therapeutic strategy in PTEN-wild-type docetaxel-resistant metastatic prostate cancer,Frontiers in Pharmacology(2024).DOI: 10.3389/fphar.2024.1331648...
In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, discusses the newest biomarkers for metastatic prostate cancer, how they inform oncologists' decisions, and challenges to overcome with targeted therapy. In season 4, episode 3 of Targeted Talks, Pedro Barata, MD, MSc, ...
Returning from ASCO 2024, Sandy Srinivas, MD, discusses the results from the PSMAfore trial, which compared lutetium-177(177Lu)-PSMA-617 with alternate androgen receptor pathway inhibitors [ARPIs] in patients with metastatic castration-resistant prostate cancer. The trial showed that177Lu-PSMA-617...
As metabolic-symbiosis promotes drug-resistance and may represent the escape mechanism during anti-angiogenic therapy, new drugs targeting metabolic-symbiosis may also be effective in cancer patients with recurrent and advanced metastatic disease. 展开 ...
Several chemotherapeutic drugs have been shown to be potentially effective in the patient with metastatic hormone refractory prostate cancer. Individual pa... RP Gibbons - 《Cancer》 被引量: 368发表: 1987年 Chemotherapy for prostate cancer - ScienceDirect Androgen deprivation in patients with metastatic...
cancer by increasing T cell activity (Kang2023). Retifanlimab was approved for metastatic or recurrent locally advanced Merkel cell carcinoma under accelerated approval, priority review, fast track, and orphan drug designation (Kang2023). In addition, retifanlimab is in phase III trials for anal ...
A new therapy for metastatic prostate cancer has shown considerable promise in early clinical trials involving patients whose disease has become resistant to current drugs. Of 30 men who received low doses of one the drugs in a multisite phase I/II trial designed to evaluate safety, 22 showed...
Over the last decade, enzalutamide and similar drugs have led to significant tumor control and increased survival time for men who have metastatic prostate cancer that continues to grow despite treatments to reduce male hormone levels. About a third of these advanced cancers, however, simply don't...